Investing
Investing Cash Flow
Royalty Pharma Investing Cash Flow increased by 43.6% to -$477.87M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 194.8%, from $503.92M to -$477.87M. Over 3 years (FY 2021 to FY 2025), Investing Cash Flow shows an upward trend with a -6.8% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
A negative value typically signals investment in future growth, while a positive value may indicate divestment or the maturity of a large investment portfolio.
Detailed definition
This metric is the net total of all cash inflows and outflows related to investing activities, including capital expendi...
Peer comparison
Most mature healthcare companies maintain a negative net investing cash flow due to ongoing R&D and infrastructure investment.
Metric ID:
net_cash_from_investingHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | -$845.50M | -$551.65M | $11.17M | -$30.18M | -$1.43B | -$558.53M | -$63.43M | -$450.66M | -$1.00B | -$86.65M | -$893.18M | -$1.19B | -$505.59M | $503.92M | -$311.98M | -$958.31M | -$847.80M | -$477.87M |
| QoQ Change | — | — | +34.8% | +102.0% | -370.3% | <-999% | +60.8% | +88.6% | -610.4% | -121.9% | +91.3% | -930.8% | -33.5% | +57.6% | +199.7% | -161.9% | -207.2% | +11.5% | +43.6% |
| YoY Change | — | — | — | — | — | -68.6% | <-999% | -110.2% | +68.4% | — | +84.5% | <-999% | -164.7% | +49.4% | +681.6% | +65.1% | +19.7% | -67.7% | -194.8% |
Range-$1.43B – $503.92M
Avg YoY Growth-465.2%
Median YoY Growth-67.7%
Current Streak2 quarters growth
Investing Cash Flow at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's investing cash flow?
- Royalty Pharma (RPRX) reported investing cash flow of -$477.87M in Q1 2026.
- How has Royalty Pharma's investing cash flow changed year-over-year?
- Royalty Pharma's investing cash flow decreased by 194.8% year-over-year, from $503.92M to -$477.87M.
- What is the long-term trend for Royalty Pharma's investing cash flow?
- Over 3 years (2021 to 2025), Royalty Pharma's investing cash flow has grown at a -6.8% compound annual growth rate (CAGR), from -$2.00B to -$1.61B.
- What does investing cash flow mean?
- The net amount of cash spent on or received from investing activities.